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l e t t e r s using logistic regression adjusted for age, dose, ALL, Ewing's sarcoma, rhabdomyosarcoma and radiotherapy (Supplementary Fig. 2a) . Analysis of the test statistics (genomic inflation factor, λ GC = 1.021) suggested that they were not influenced by cryptic population stratification ( Supplementary Fig. 2b ). Eighteen variants tagging nine distinct linkage disequilibrium (LD) blocks (r 2 > 0.9 and D′ > 0.9 in the 1000 Genomes Project CEU (European ancestry) reference data set) with P < 1.0 × 10 −5 were prioritized for further analysis in an independent patient population (Supplementary Table 2 ).
In stage 2, we genotyped one GWAS candidate variant per LD block in an independent Dutch population of patients of European ancestry with childhood cancer (96 patients; 22 cases and 74 controls). In this cohort, the patient demographics for cases and controls were similar, with the exception that cases had higher cumulative anthracycline exposure ( Supplementary Table 1 ). Genetic associations were tested using logistic regression with adjustment for cumulative anthracycline dose. Of the nine candidate variants tested, only rs2229774, a nonsynonymous coding variant (p.Ser427Leu) in RARG (retinoic acid receptor γ), was replicated (P = 0.0043, odds ratio (OR) = 4.1 (1.5-11.5); Fig. 1 and Table 1) .
Given that the stage 1 and 2 cohorts differed in some patient characteristics, such as anthracycline dose, the replication analysis merits circumspect interpretation. To address this, we performed additional genetic association analyses by logistic regression with the prioritized GWAS variants in subsets of cases and controls stratified by low to moderate (≤250 mg/m 2 ) or high (>250 mg/m 2 ) levels of anthracycline exposure (Supplementary Table 3 ). The rs2229774 SNP in RARG was associated with ACT in stages 1 and 2 and in the combined analysis at both low to moderate (P = 4.1 × 10 −4 , 0.0036 and 9.8 × 10 −6 , respectively) and high (P = 0.0021, 0.084 and 8.7 × 10 −4 , respectively) anthracycline doses. By contrast, none of the other top GWAS candidate SNPs were significantly associated with ACT in the replication cohort, even with low to moderate levels of anthracycline exposure. Logistic regression analyses in the stage 1 cohort indicated that rs2229774 in RARG was similarly associated with early-onset chronic ACT (n = 16 cases; P = 2.8 × 10 −4 , OR = 7.3 (2.3-22.9)) and late-onset chronic ACT (n = 16 cases; P = 5.0 × 10 −3 , OR = 5.8 (1. 7-19.4) ).
In stage 3, we examined the association of rs2229774 in RARG with ACT in a third cohort of non-European patients representative of different ancestry groups (80 patients; 19 cases and 61 controls; Supplementary Table 4 ). Because of the absence of rs2229774 in RARG from controls, logistic regression with adjustment for population stratification and other clinical covariates could not be performed in this cohort ( Supplementary Table 5 ). Instead, the association of rs2229774 with ACT in this cohort was analyzed by genotypic test. rs2229774 was highly associated with ACT (P = 1.2 × 10 −4 ; Table 1 ) in the stage 3 cohort and in each of the four non-European populations separately (African, Aboriginal Canadian, Hispanic and East Asian; Supplementary Table 5 ). Notably, genotypic association testing reached genome-wide significance in the discovery and combined cohorts (P < 5.0 × 10 −8 ; Table 1 ).
The stage 3 cohort, comprising four distinct populations, was assessed for population stratification using the genomic inflation factor and principal-component analysis (PCA). Principal Figure 1 A pharmacogenetic association with susceptibility to ACT is situated in RARG. Top, association results are shown for genotyped (circles) and imputed (squares) SNPs along with recombination rates for a 122-kb region on chromosome 12q13.13. Each point represents the nominal P value (left y axis) for the stage 1 cohort. P values are from logistic regression analysis using an additive model, adjusted for age, cumulative anthracycline dose, tumor type (ALL, Ewing's sarcoma or rhabdomyosarcoma) and cardiac radiation therapy. SNPs are colored according to their pairwise correlation (r 2 ) with rs2229774 (purple circle) using the 1000 Genomes Project CEU reference population. Overlaid are recombination rates (right y axis) for estimating putative recombination hotspots, also based on the 1000 Genomes Project CEU population. Bottom, LD (D′) based on the 1000 Genomes Project CEU population depicted for this region similarly demonstrates that the haplotype associated with ACT is localized to RARG. LD plots were created using Haploview and are color coded as follows: white (D′ < 1, logarithm of odds (LOD) < 2); blue (D′ = 1, LOD < 2); pink shading (D′ < 1, LOD ≥ 2); and bright red (D′ = 1, LOD ≥ 2). npg l e t t e r s components 1-10 did not significantly differ between cases and controls (P > 0.14), and the λ GC value of 0.941 suggests no confounding effect of population stratification on the genetic association of rs2229774 with ACT in this cohort. In line with the reported high incidence rate of ACT in studies conducted in India 30 and Pakistan 31 and in African-American patients in the United States 23, 24 , the A allele (minor allele) of rs2229774 in RARG was more frequent in South Asian (22%) and African (11%) populations than in European (6%) and Hispanic (5%) ones. By contrast, rs2229774 was very rare in East Asian populations (0%) (1000 Genomes Project). It will be interesting to correlate the frequency of rs2229774 with the incidence of ACT in children of different ancestry as data for multiple-ancestry studies become available for comparison. A meta-analysis of all study populations (456 patients; 73 cases and 383 controls) using logistic regression adjusted for age, dose, ALL, radiotherapy, Ewing's sarcoma and rhabdomyosarcoma showed that rs2229774 in RARG was significantly associated with ACT (P = 5.9 × 10 −8 , OR = 4.7 (2.7-8.3)), with significance surpassing the Bonferroni-adjusted threshold with multiple-testing correction and no significant heterogeneity across the GWAS and two independent replications (P value for heterogeneity (P het ) = 0.402). Overall, rs2229774 carriers (AA or AG genotype) had significantly increased odds of developing ACT in comparison to non-carriers (OR = 5.2 (3.0-9.0), P = 5.9 × 10 −10 ).
To fine map the rs2229774 association with ACT, we imputed variants on chromosome 12 using the stage 1 cohort and the 1000 Genomes Project CEU reference population, and we tested the association of these variants with ACT by logistic regression ( Fig. 1) . Of the 1,005,286 imputed SNPs, 3 were associated with ACT at P < 1.0 × 10 −5 (rs11170481, rs73309171 and rs57789211; Table 2 ). These variants were all located in introns of RARG, were highly correlated with each other (D′ ≥ 0.91, r 2 ≥ 0.54) and were in high LD with rs2229774 (D′ = 1.00, r 2 ≥ 0.55). Because the associations of the imputed variants with ACT were similar to that for rs2229774 and because logistic regression with conditioning on rs2229774 abolished these associations ( Table 2) , the nonsynonymous coding variant rs2229774 was prioritized for functional characterization to gain biological insight into its association with ACT.
Retinoic acid receptors bind to DNA regulatory sequences termed retinoic acid response elements (RAREs) and transcriptionally co-regulate downstream gene expression in response to their agonist, all-trans retinoic acid (ATRA) 32 . Notably, RARG can both activate and repress transcription in response to ATRA 33 . To explore the functional properties of rs2229774 (encoding RARG Ser427Leu), we first examined transactivation by the mutant protein of RARG regulatory elements and then identified a putative role in the dysregulation of a critical gene involved in the development of ACT (Online Methods). In HEK293T cells expressing RARG Ser427Leu, the ATRA-inducible transcriptional activation of a RARE-coupled luciferase reporter was significantly reduced (P = 0.0011) in comparison to cells expressing wild-type RARG ( Fig. 2a) . Immunoblot analysis verified that the wildtype and variant RARG proteins were detected at similar levels in HEK293T cell lysate ( Fig. 2a, inset) . The significant 17% decrease in RARG activity conferred by the rs2229774 variant may be an underestimation, as endogenous retinoic acid receptors were present in this assay. These results suggest that the dysregulation of an RARG-regulated gene might underlie the association of rs2229774 with ACT.
Anthracyclines are mechanistically and genetically linked with topoisomerase IIβ (TOP2B). Anthracyclines exert their anticancer activity by binding and inhibiting topoisomerase II (ref. 34) . In addition, Top2b is necessary for the development of ACT in a mouse model 35 , whereas, in a rat cardiomyoblast cell line (H9c2), Top2b levels are decreased by the ACT cardioprotectant dexrazoxane 36 . RARG expression has been reported as being 'particularly high' in the heart (Nuclear Receptor Signaling Atlas) and is highly induced in mouse cardiac cells after cardiac injury 37 . Because RARG has been shown to bind to the Top2b promoter 38 , this gene represents one potential npg l e t t e r s candidate of RARG Ser427Leu dysregulation. We found that Top2b expression in H9c2 cells was significantly decreased (P < 0.0001) when human RARG was expressed, and this effect was further exacerbated with the addition of ATRA (Fig. 2b) . By contrast, the RARG Ser427Leu variant did not repress Top2b expression as effectively as wild-type RARG (Fig. 2c) . Taken together, these results demonstrate that RARG represses Top2b expression and that rat cardiomyoblasts expressing RARG carrying rs2229774 express higher basal levels of Top2b, consistent with increased susceptibility to ACT. We have identified a new genetic biomarker for ACT, rs2229774 in RARG, using a three-stage genetic association study combined with biological functional analyses. This discovery, despite originating from a relatively small number of patients, is likely due to the large effect size of this variant. In general, sample size limitation remains a major challenge in pediatric cancer pharmacogenomic studies 39, 40 , where the need for a homogenous study population and well-defined clinical phenotypes results in reduced numbers of study subjects, in particular affected individuals. However, clinically relevant genetic markers of severe ADRs, such as ACT, abacavir-induced hypersensitivity reaction and carbamazepine-induced Stevens-Johnson syndrome, are expected to have large effect sizes, and the number of patients, particularly affected individuals, required to uncover these genetic associations from large-scale genome screens has therefore been shown to be in the range of 10-100 patients 41 , similar to the number in this study.
Our study had ≥80% power to detect genome-wide associations at P ≤ 5 × 10 −8 with per-allele OR ≥ 4.5 and minor allele frequency (MAF) ≥ 0.10. There are likely additional genetic contributions to ACT, including previously reported associations 4-22 that were not uncovered in the current GWAS, potentially owing to the strict ACT case definition and resulting small patient numbers used in this study. For example, ABCC2 (MRP2), HNMT and POR, although not reaching genome-wide significance in this study, exhibited strong trends of association (P < 0.05; Supplementary Table 6 ) in the same direction of effect as previously reported 4, 8, 12, 16, 22 . These findings underscore the complementary nature of GWAS and candidate gene association studies in identifying variants associated with pharmacogenomic traits.
In agreement with in silico predictions, our in vitro studies demonstrate that rs2229774 causes a relatively tolerated amino acid substitution that results in a moderate but significant reduction in transcriptional activation from RARE elements. We established a genetic interaction between RARG and Top2b, where expression of the latter is significantly repressed by RARG in the presence of ATRA. Notably, the treatment of acute promyelocytic leukemia with high cumulative doses of anthracycline and ATRA has resulted in a significantly lower incidence of ACT 42, 43 . We further showed that rs2229774 causes derepression of Top2b in cardiomyoblasts, directly linking this variant with ACT. These data are consistent with a model where rs2229774 carriers have higher basal levels of TOP2B in cardiomyocytes, conferring increased susceptibility to cardiotoxicity when these patients are treated with anthracyclines. Nevertheless, despite rs2229774 encoding a nonsynonymous variant, it is plausible that the rs2229774 haplotype confers increased susceptibility to ACT through a regulatory mechanism. To our knowledge, a comprehensive analysis of RARG-regulated gene expression in cardiomyocytes has not been reported, and it is possible that additional genes in cardiomyocytes may contribute to the development of ACT when dysregulated in carriers of rs2229774 in RARG. For example, ATRA-regulated gene expression in cardiomyocytes is important for cardiac development and the progression of cardiomyocyte hypertrophy [44] [45] [46] , although the specific contribution of RARG to these processes is unknown.
The identification of rs2229774 in RARG, which is genetically and functionally linked to ACT, provides a clinical tool that may be used to predict genetic risk for ACT and improve risk stratification. ACT is a clinically significant ADR, and carriers of rs2229774 have fivefold increased odds of ACT. This new finding merits further exploration of the role of RARG in ACT and of the clinical usefulness of the rs2229774 variant in RARG for predictive testing to inform ACT risk assessment. 
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We acknowledge the participation of all the patients and families who took part in this study across Canada, the Netherlands and the United States. Figure 1 . In stage 1, a total of 280 European-Canadian patients (32 cases and 248 controls) were used as the discovery cohort and genotyped on the Illumina Infinium HumanOmniExpress panel (~740,000 markers), to perform a GWAS for ACT (stage 1). Markers that reached P < 1.0 × 10 −5 (ref. 47) in the discovery cohort were tested for replication in 96 European-Dutch patients (22 cases and 74 controls) in stage 2. rs2229774 in RARG was further tested for association with ACT in non-European populations in stage 3. We also performed a combined analysis for all European-ancestry patients (stages 1 and 2) and an overall association test for rs2229774 using all populations (stages 1-3). In addition, we performed genetic fine-mapping analyses of the associated region and functionally characterized rs2229774 in vitro.
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Study design. The study design is briefly outlined in Supplementary
Genetic ancestry was self-reported and ascertained by PCA using the EIGENSTRAT method with SNP genotype data sets derived from the customized GWAS Illumina Infinium HumanOmniExpress panel (738,432 markers) for Canadian patients, a custom Illumina VeraCode ADME Core Panel (4,536 markers) for Dutch patients and a custom Illumina Infinium ADME Core Panel (7,907 markers) for US patients.
Analysis of clinical data.
This study was approved by the individual ethics committees or institutional review boards of the universities and institutions where patients were enrolled. Written informed consent or assent was obtained from patients or their parents or legal guardians in accordance with the Declaration of Helsinki as revised in 2008.
Patients' medical records were reviewed before genotyping by a clinical pharmacologist, a cardiologist, an oncologist and an ADR surveillance clinician, who reviewed the echocardiogram test results and other clinical information. The demographic, clinical and therapeutic information was extracted from these medical records and included the following data: demographics, disease characteristics, chemotherapy, diagnostic echocardiograms to document baseline and follow-up cardiac function and any cardiac compromise and its severity and any symptoms and/or signs consistent with ACT. All patients were children ≤18 years of age at the time of cancer diagnosis who received anthracyclines as part of their chemotherapy protocol, had normal cardiac function before anthracycline chemotherapy, and were recruited from outpatient clinics and inpatient units. ACT was monitored by echocardiograms according to The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. The recommended frequency of echocardiograms is every year, every 2 years or every 5 years after treatment, depending on age at the time of treatment, whether radiation was used with potential impact to the heart and the cumulative anthracycline dose. Grading of ACT based on this detailed clinical characterization was performed using the Cancer Therapy Evaluation Program CTCAEv3 as previously described 12, 13 . Patients with serious ACT were defined as those with grade 2 or higher CTCAE impairment of cardiac function after treatment with anthracycline.
ACT was defined as early-or late-onset left ventricular dysfunction as assessed by echocardiogram measurements using SF (percentage of end-diastolic dimensions lost during systole) and/or symptoms (dyspnea, orthopnea and/or fatigue) and/or signs (edema, hepatomegaly and/or rales) of cardiac compromise requiring intervention on the basis of CTCAEv3. Owing to variability in echocardiographic measurements, a conservative SF threshold of SF ≤ 24% was used to define asymptomatic cases who developed ACT. All cases had grade 2 or higher ACT. Grade 2-4 ACT is the point at which anthracycline chemotherapy protocols recommend clinical intervention such as treatment for heart failure, halting or reducing anthracycline doses, and switching to alternate treatments. Early-onset chronic ACT was defined as developing less than 1 year after the start of treatment 48, 49 , whereas late-onset chronic ACT was defined as developing more than 1 year after the start of treatment 50, 51 , as ventricular dysfunction, heart failure and arrhythmias can occur years or even decades after the discontinuation of anthracycline therapy 50, 51 . To exclude transient acute ACT, only echocardiograms obtained ≥21 d after an anthracycline dose were considered. To exclude cardiotoxicity unrelated to anthracycline chemotherapy, patients with no baseline echocardiogram were excluded from the study. Controls had no signs or symptoms of cardiac compromise at study participation (grade 0). Owing to the delayed onset of ACT in some patients, SF ≥ 30% with ≥5 years of follow-up after the end of anthracycline treatment was used to define controls. Cumulative anthracycline exposure was calculated using the doxorubicin isotoxic equivalent 52 , and stratification by cumulative dose into low to moderate (≤250 mg/m 2 ) and high (>250 mg/m 2 ) levels of anthracycline exposure was performed as previously described 6, 14, 53 where appropriate. Radiation therapy included significant radiation exposure to the heart or surrounding tissue. This included mantle and mediastinal radiation, whole-lung radiation, whole-abdomen or upper abdominal radiation, left-side flank radiation and total-body irradiation.
Study populations. Canadian patient populations. We genotyped 434 pediatric oncology patients treated with anthracyclines who were recruited from 13 pediatric oncology units from across Canada between February 2005 and April 2011 (refs. 12,13) . A total of 13 samples failed quality control. For the 421 remaining patients (average call rate = 99.5%), we performed PCA with the GWAS Illumina 740K SNP genotype data set to determine the population structure and defined four distinct population clusters comprising European, African, East Asian and Aboriginal Canadian individuals. Patients with genetic ancestry that fell outside of these four population clusters were excluded from further analysis. We excluded an additional 27 patients with CTCAE grade 1 toxicity (24% < SF < 30%). A total of 97 patients were excluded, and 337 patients were available for further analyses: Europeans (n = 280 patients; 32 cases and 248 controls), Africans (n = 11 patients; 2 cases and 9 controls), East Asians (n = 31 patients; 8 cases and 23 controls) and Aboriginal Canadians (n = 15 patients; 4 cases and 11 controls).
Dutch patient population. We recruited 128 pediatric oncology patients treated with anthracyclines from the Emma Children's Hospital/Academic Medical Center in Amsterdam between July 2009 and April 2011 (refs. 12,13) . We performed PCA using the Illumina 4.5K SNP genotype data set generated for these patients 54 We performed a detailed clinical assessment of these patients and excluded 10 patients who had missing or abnormal baseline echocardiogram readings, 8 patients with CTCAE grade 1 toxicity (24% < SF < 30%) and 102 patients with insufficient cardiac follow-up data (either SF > 30% but <5 years of follow-up (97 patients) or SF < 24% but <21 d from the end of treatment (5 patients)). PCA identified four clusters of the remaining patients aligning with their self-reported ancestries of Hispanic, Asian, African-American and European. The cluster of 23 Hispanic patients (5 cases and 18 controls) was selected for analysis in stage 3.
DNA extraction and molecular genotyping.
Genotyping experiments were conducted at the CPNDS genotyping core facility, Child and Family Research Institute, University of British Columbia (Vancouver, British Columbia, Canada). All patients provided a biological specimen for DNA extraction. Genomic DNA was extracted using the QIAamp DNA purification system (Qiagen) and quantified by Quant-iT PicoGreen assay (Invitrogen), according to the manufacturer's protocols. Whole-genome amplification was performed before genotyping for all samples available at a low concentration (≤50 ng/µl) and/or low volume (≤20 µl). Laboratory assistants were blinded to the casecontrol status of the patients genotyped in the study. To ensure the accuracy of all genotyping results, multiple positive and negative controls and replicate samples were included in all genotyping assays and plates. The concordance of genotype calls between replicate genotyped samples was 100%.
The GWAS was performed using a customized Illumina Infinium HumanOmniExpress assay containing 738,432 SNPs according to the manufacturer's instructions. Genotypes were called with the Illumina GenomeStudio software package, and SNPs were clustered using the Illumina 740K cluster file. A detailed GWAS quality control procedure was performed for all SNPs and samples before analysis using the Illumina GenomeStudio software package.
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To prevent spurious genetic associations, all patients within each study population shared the same genetic ancestry, which was self-reported and ascertained by PCA 58 . Then, for each study cohort, we computed the genomic inflation factor (λ GC ) to identify the presence of within-ancestry group finescale population structures or admixtures or inflation of the test statistics due to population stratification 59 : stage 1 cohort (based on 657,694 SNPs), λ GC = 1.021; stage 2 cohort (based on 4516 SNPs), λ GC = 1.014; and stage 3 cohort (based upon 7798 mutual SNPs available to all patients), λ GC = 0.941. We performed meta-analyses of all European-ancestry patients (stages 1 and 2) and of all study populations (stages 1-3) using SVS/HelixTree 8.1.1 and calculated the heterogeneity by Cochran's Q statistics to assess the diversity across the different study populations using Comprehensive Meta-Analysis software. The Manhattan plot of −log 10 (P values) and the quantile-quantile distribution were generated using SVS/HelixTree 8.1.1. The regional association plot for the associated genomic region was created using LocusZoom. LD plots were created using Haploview and color coded as follows: white (D′ < 1, LOD < 2); blue (D′ = 1, LOD < 2); pink shading (D′ < 1, LOD ≥ 2); and bright red (D′ = 1, LOD ≥ 2).
Statistical analyses of the functional data provided in Figure 2 showed that all data ( Fig. 2a-c) were normally distributed when assessed by the D' Agostino and Pearson omnibus normality test. Variation coefficients were estimated as follows: wild-type RARG, 23.77%; S427L RARG, 31.28% (Fig. 2a) ; untransfected, 9.30%; wild-type RARG, 9.37%; wild-type RARG + ATRA, 7.33% (Fig. 2b) ; and wild-type RARG, 16.48%; Ser427Leu RARG, 22.69% (Fig. 2c) . F tests showed the variances between groups significantly differed in Figure 2b and Figure 2c .
